Key result
Liver-targeting thyroid hormone receptor beta-agonists show therapeutic potential for improving hepatic lipid metabolism.
Why the study?
Thyroid hormones regulate energy balance and lipid metabolism, and liver-targeting receptor beta-agonists provide a therapeutic opportunity for liver lipid disorders. This review examines the physiological mechanisms of thyroid hormone regulation and their implications for dyslipidaemia, cardiovascular disease, obesity, metabolic syndrome, and metabolic dysfunction-associated steatotic liver disease and steatohepatitis.
Answers are grounded in this paper and cite their sources.
This review highlights the physiological mechanisms by which thyroid hormones regulate lipid metabolism and the therapeutic potential of liver-targeting thyroid hormone receptor beta-agonists like resmetirom for dyslipidaemia and MASLD/MASH.
Thyroid hormones act as key regulators of energy balance and lipid metabolism and affect the liver, adipose tissue, skeletal muscle and cardiovascular system. Triiodothyronine (T3) the active hormone, exerts genomic and nongenomic effects on lipid synthesis, fatty acid oxidation, cholesterol uptake, lipoprotein concentrations, bile acid production and reverse cholesterol transport. These effects are regulated mainly by thyroid hormone receptors α and β, and receptor β in particular plays a role in hepatic lipid regulation. Typical laboratory findings in hypothyroidism are high total cholesterol, LDL cholesterol, apolipoprotein B and, sometimes, triglycerides. These are abnormalities due to decreased LDL receptor activity, decreased clearance of lipoprotein and altered fatty acid oxidation and VLDL metabolism. Subclinical hypothyroidism can cause similar disturbances, but their severity depends upon the level of TSH, age, sex, adiposity and metabolic status. Hyperthyroidism, on the other hand, tends to decrease the levels of total and LDL cholesterol, the effects of which are dependent on the severity of the disease and treatment. The molecular mediators are sterol regulatory element-binding proteins, PCK9s, LXRs, PPARs, FGFs and the bile acid pathways. Liver-targeting receptor β-agonists, such as resmetirom, provide a therapeutic opportunity for liver lipid disorders. This review looks at these mechanisms and their implications for dyslipidaemia, cardiovascular disease, obesity, metabolic syndrome and metabolic dysfunction-associated steatotic liver disease and, in particular, metabolic dysfunction-associated steatohepatitis.
No takes yet. Share an insight, caveat, or question.
AL-Badri et al. (2026) conducted a review in Thyroid disorders (hypothyroidism, subclinical hypothyroidism, hyperthyroidism) and lipid/metabolic disorders (dyslipidaemia, cardiovascular disease, obesity, metabolic syndrome, MASLD/MASH). Thyroid hormones (T3) and liver-targeting thyroid hormone receptor beta-agonists (resmetirom) was evaluated. Thyroid hormones regulate lipid metabolism via alpha and beta receptors, and liver-targeting receptor beta-agonists like resmetirom offer therapeutic potential for hepatic lipid disorders.
Synapse has enriched 8 closely related papers on similar clinical questions. Consider them for comparative context: